Eli Lilly and Company LLY

1,183.46 1.57 0.13% as of 25 Sep
Market cap
$1.11T
P/E
39.7×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Eli Lilly and Company (LLY) EV/EBITDA

As of 25 September 2026, Eli Lilly and Company (LLY) trades at a EV/EBITDA of 30.8×. Over the past ten years it has ranged from 16.9× (December 2016) to 93.6× (October 2024); the current reading is higher than 62% of that period. That is above the Drug Manufacturers General industry median of 13.9× and above the Healthcare sector median of 10.4×.

EV/EBITDA, daily

Annual

Period EV/EBITDA Change
FY2025 35.3× (28.22%)
FY2024 49.2× (28.67%)
FY2023 69.0× 73.88%
FY2022 39.7× 19.01%
FY2021 33.3× 48.09%
FY2020 22.5× 3.21%
FY2019 21.8× (7.08%)
FY2018 23.5× (7.91%)
FY2017 25.5× 49.17%
FY2016 17.1× (24.37%)

Quarterly

Period EV/EBITDA Change
Jun 2026 31.2× 22.15%
Mar 2026 25.6× (27.59%)
Dec 2025 35.3× 20.20%
Sep 2025 29.4× (25.39%)
42 more quarters

Against its own ten years

Low 16.9× High 93.6×
Ten-year median 26.6×
Current reading's percentile 62

EV/EBITDA against peers

Company EV/EBITDA
PFE Pfizer Inc. compare 10.5×
AZN AstraZeneca PLC compare 13.9×
NVS Novartis AG compare 14.0×
AMGN Amgen Inc. compare 16.2×
JNJ Johnson & Johnson compare 19.2×
ABBV AbbVie Inc. compare 20.8×
MRK Merck & Co., Inc. compare 30.0×
LLY Eli Lilly and Company 30.8×
GILD Gilead Sciences, Inc. compare 804×
Drug Manufacturers General industry median 13.9×
Healthcare sector median 10.4×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on LLY